FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Praxis Precision Medicines, Inc. reported that the U.S. Food and Drug Administration has accepted for review its New Drug Application for ulixacaltamide HCl to treat essential tremor in adults. The FDA set a target action date under the Prescription Drug User Fee Act of January 29, 2027 and indicated it is not planning to hold an advisory committee meeting.
Positive
- None.
Negative
- None.
Insights
FDA acceptance moves ulixacaltamide into full review with a defined decision date.
The FDA has accepted Praxis Precision Medicines' New Drug Application for ulixacaltamide HCl in essential tremor, meaning the submission passed the agency’s initial completeness and filing standards. The drug is now in the formal review phase for adult essential tremor treatment.
The FDA set a target action date of January 29, 2027 under the Prescription Drug User Fee Act, giving a clear timeline for a regulatory decision. The agency also stated it is not planning to hold an advisory committee meeting, which can indicate that questions may be addressable within the review division, though outcomes remain uncertain until the action date.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
FDA action date: January 29, 2027
1 metrics
FDA action date
January 29, 2027
Target action date under Prescription Drug User Fee Act for ulixacaltamide NDA
Key Terms
New Drug Application, essential tremor, Prescription Drug User Fee Act, advisory committee meeting, +1 more
5 terms
New Drug Application regulatory
"announced that the U.S. Food and Drug Administration ... has accepted for review its New Drug Application for ulixacaltamide HCl"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
essential tremor medical
"New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults"
Essential tremor is a neurological condition that causes involuntary shaking, usually in the hands or arms, which can make everyday tasks difficult. While it is not life-threatening, it can impact a person's ability to perform precise movements. For investors, understanding such health conditions is important because they can influence a person's productivity, decision-making, and overall financial stability.
Prescription Drug User Fee Act regulatory
"The FDA has set a target action date under the Prescription Drug User Fee Act of January 29, 2027"
A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.
advisory committee meeting regulatory
"and is not planning to hold an advisory committee meeting"
A regulatory advisory committee meeting brings together independent experts to review clinical, safety, or technical data about a drug, medical device, or other regulated product and offer nonbinding recommendations to the agency that oversees approvals. Investors watch these meetings like a public review panel because the experts’ questions, concerns or endorsements can strongly influence whether a product clears regulatory hurdles, affecting a company’s future revenue and stock value.
U.S. Food and Drug Administration regulatory
"announced that the U.S. Food and Drug Administration (the “FDA”) has accepted for review"
The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.
FAQ
What regulatory milestone did Praxis Precision Medicines (PRAX) announce for ulixacaltamide?
Praxis announced that the FDA accepted its New Drug Application for ulixacaltamide HCl to treat essential tremor in adults. This moves the therapy into full regulatory review after the FDA determined the submission was sufficiently complete for evaluation.
What is the FDA target action date for Praxis (PRAX) ulixacaltamide NDA?
The FDA set a target action date of January 29, 2027 for the ulixacaltamide HCl New Drug Application. This Prescription Drug User Fee Act date is when the agency aims to complete its review and issue a regulatory decision on the application.
Is the FDA planning an advisory committee for Praxis (PRAX) ulixacaltamide?
The FDA indicated it is not planning to hold an advisory committee meeting for the ulixacaltamide HCl New Drug Application. This means review will proceed within the agency’s internal teams without a public expert panel meeting based on current plans.
What condition is Praxis (PRAX) targeting with ulixacaltamide HCl?
Ulixacaltamide HCl is being reviewed by the FDA for the treatment of essential tremor in adults. Essential tremor is a movement disorder characterized by involuntary shaking, and the application focuses specifically on adult patients with this condition.
Does FDA acceptance of the NDA mean ulixacaltamide is approved for Praxis (PRAX)?
FDA acceptance of the New Drug Application does not mean ulixacaltamide is approved. Acceptance confirms the filing is complete enough for review, after which the FDA will evaluate safety and effectiveness and decide by the January 29, 2027 target date.